Copd Bronchitis
8
3
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Comparison of Several Oxygenation Targets With Different Oxygen Interfaces - Impact on Oxygen Flow Rates
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
Gala Early Feasibility Study of RheOx
NBMI - Clinical Study on COPD
Muco-ciliary Cleansing of Lungs in COPD With and Without a Salt Particle Inhaler
Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients